Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleSystemic Lupus Erythematosus

Zoster after Cyclophosphamide for Systemic Lupus Erythematosus or Vasculitis: Incidence, Risk Factors, and Effect of Antiviral Prophylaxis

Camille Garnier, David Ribes, Dominique Chauveau, Antoine Huart, Grégory Pugnet, Daniel Adoue, Grégoire Prevot, Laurent Alric, Pierre Delobel, Hélène Derumeaux, Catherine Mengelle, Laurent Sailler and Guillaume Moulis
The Journal of Rheumatology November 2018, 45 (11) 1541-1548; DOI: https://doi.org/10.3899/jrheum.180310
Camille Garnier
From Service de Maladies Infectieuses et Tropicales; Département de Néphrologie et transplantation d’organes, et Centre de Référence Maladies Rénales Rares; Service de Médecine Interne; CIC 1436; Service de Rhumatologie et Médecine Interne; Service de Pneumologie; Service de Médecine Interne, Fédération Digestive; Département d’information médicale; Service de Virologie, CHU de Toulouse; UMR 1027, Inserm-Université de Paul Sabatier, Toulouse, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Ribes
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dominique Chauveau
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antoine Huart
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Grégory Pugnet
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Adoue
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Grégoire Prevot
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laurent Alric
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pierre Delobel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hélène Derumeaux
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catherine Mengelle
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laurent Sailler
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guillaume Moulis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Guillaume Moulis
  • For correspondence: moulis.g@chu-toulouse.fr
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

Objective. To assess the incidence and the risk factors for zoster in patients exposed to intravenous cyclophosphamide (CYC) for systemic vasculitis or systemic lupus erythematosus (SLE), as well as the protective effect of prophylaxis by valacyclovir (VCV).

Methods. This retrospective study included all adults treated by intravenous CYC for SLE or systemic vasculitis between 2011 and 2015 at Toulouse University Hospital, France. Zoster occurrence was recorded using medical chart review, laboratory data, and patient interviews. Univariate Cox models were computed to assess the risk factors for zoster and the protective effect of prophylaxis by VCV.

Results. The cohort consisted of 110 patients (81 systemic vasculitis and 29 SLE). During a mean followup of 3.4 years after CYC initiation, 10 cases of zoster occurred, leading to an overall incidence of 27.9/1000 patient-years (95% CI 15.2–50.6); it was 59.4/1000 patients (95% CI 27.5–123.6) during the year after CYC initiation. Four patients experienced persistent postherpetic neuralgia. Probable risk factors were lymphopenia < 500/µl at CYC initiation (HR 5.11, 95% CI 0.94–27.93) and female sex (HR 4.36, 95% CI 0.51–37.31). The incidence was higher in patients with SLE (HR as compared with systemic vasculitis patients = 2.68, 95% CI 0.54–13.26). None of the 19 patients exposed to VCV during the followup developed zoster.

Conclusion. The incidence of zoster is high in systemic vasculitis and in patients with SLE exposed to intravenous CYC. CYC may favor postherpetic neuralgia. Prophylaxis by VCV should be considered, particularly in cases of lymphopenia < 500/µl at CYC initiation and during the year after.

Key Indexing Terms:
  • HERPES ZOSTER
  • SYSTEMIC LUPUS ERYTHEMATOSUS
  • SYSTEMIC VASCULITIS
  • ANCA-ASSOCIATED VASCULITIS
  • VALACYCLOVIR
  • EPIDEMIOLOGY

Immunocompromised patients are at risk for varicella-zoster-virus (VZV) reactivation1,2. The incidence of zoster in this population is between 2- and 10-fold higher than in the general population2. This setting includes patients with autoimmune diseases, such as systemic lupus erythematosus (SLE), rheumatoid arthritis, inflammatory bowel diseases, or systemic vasculitis2,3,4,5,6. Further, the increased risk of zoster in these patients when treated with corticosteroids, biologics, or nonbiologic immunosuppressive drugs is demonstrated7.

Patients with SLE are particularly at risk of developing zoster2,5, with an incidence ranging from 6.4 to 37.7/1000 patient-years (PY) in observational studies8,9,10,11. Age-, sex-, and treatment-adjusted relative risk has been estimated to be 2.45 (95% CI 1.77–3.40) compared to the general population12. Exposure to corticosteroids12,13, exposure to immunosuppressive drugs including oral and intravenous cyclophosphamide (CYC)13,14, renal impairment, and lymphopenia have been described as main risk factors for zoster in these patients13.

In contrast, few data are available on zoster occurrence in patients with systemic vasculitis. However, it is a concern in granulomatosis with polyangiitis (GPA) patients15,16. A single study assessed its incidence, derived from the Wegener’s Granulomatosis Etanercept Trial (WGET), and it was estimated to be 45.0/1000 PY (95% CI 27.0–70.0)17. The association of corticosteroids and CYC seems a strong risk factor for zoster in patients with GPA15. Kidney failure may also be associated with an increased zoster incidence in these patients17.

Intravenous CYC is a strong immunosuppressive drug still indicated in the treatment of severe flares of SLE18,19 and systemic vasculitis20, in association with corticosteroids. Exposure to CYC increases the risk of severe infection, particularly during the year after the first exposure21,22.

However, no study has been focused on the risk of zoster in systemic vasculitis and patients with SLE exposed to pulse intravenous CYC. The suspected risk factors (lymphopenia, kidney failure) need to be confirmed in this population. Moreover, the efficacy of antiviral prophylaxis to prevent zoster occurrence, demonstrated in stem cell transplantation23,24, is unknown in this population.

The aims of our study were to describe the incidence of zoster in patients exposed to pulse intravenous CYC for systemic vasculitis or SLE, to describe the cases of zoster in this population, and to assess the risk factors for zoster as well as the protective effect of prophylaxis by valacyclovir (VCV).

MATERIALS AND METHODS

Design

We conducted an observational, retrospective, monocentric study at Toulouse University Hospital, a French 2986-bed tertiary hospital.

Patients

We selected all the patients who were prescribed pulse intravenous CYC over 5 years, between January 1, 2011, and December 31, 2015, from the hospital pharmacy database. Medical charts were reviewed and diagnoses ascertained using international criteria25,26. Patients meeting inclusion criteria were those who were adults (≥ 18 yrs of age), were treated for SLE or systemic vasculitis, had no previous exposure to CYC, and were followed at Toulouse University Hospital.

Outcomes

Zoster occurrence was searched using the following sources: medical chart reviews, VZV PCR at the Virology Department of Toulouse University Hospital, and phone interviews with the patients and/or their general practitioners.

Zoster characteristics, time of occurrence from CYC and other immunosuppressive drugs, and zoster complications were described. Postherpetic neuralgia was defined as the persistence of dermatomal pain at least 90 days after the acute zoster rash appearance27.

Statistical analyses

The incidence estimates of zoster during the overall followup and during the first year after the first pulse of CYC were calculated with their 95% CI intervals.

Risk factors for zoster occurrence during the year after the first exposure to CYC were assessed using Cox models. Covariables were the following: age (≥ 50 vs < 50 yrs, 50 yrs being the median age in our cohort, and being close to the mean age of zoster occurrence in France28), sex, the presence of diabetes mellitus, active cancer, renal failure at CYC initiation (defined by an estimated glomerular filtration rate < 60 ml/min/1.73m2 using the Chronic Kidney Disease Epidemiology Collaboration formula29), lymphopenia at CYC initiation (defined as a lymphocyte count < 1000/µl), the cumulative dose of CYC, the exposure to immunosuppressive drugs other than corticosteroids and CYC, and prophylaxis with VCV. Because of the expected low number of zoster events, only univariate analyses were computed.

All analyses were computed using the SAS V9.3TM software (SAS Institute).

Ethical issues

This study is in accordance with the Declaration of Helsinki. According to French law, patients were informed of data collection and of the possibility to refuse it during their hospital stay. Patients were reminded of this during phone interviews. The study was registered to the French national committee on data privacy (Commission Nationale de l’Informatique et des Libertés – CNIL, No. 2096181).

RESULTS

Selection of the population

Out of 360 patients treated with intravenous CYC during the study period, 161 were treated for SLE or systemic vasculitis. Fifty-one patients were further excluded (26 because of followup out of Toulouse University Hospital and 25 previously treated by CYC). No patient refused to participate. Eventually, 110 patients were included in the analyses: 29 with SLE and 81 with systemic vasculitis, including 68 with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV; 26 with GPA, 20 with microscopic polyangiitis, 11 with eosinophilic granulomatosis with polyangiitis, and 11 with unclassified AAV), 5 with polyarteritis nodosa, 7 with unclassified vasculitis and 1 cryoglobulinemic vasculitis. An interview of the patients and/or of their general practitioners, in addition to medical chart and laboratory testing review, was possible for 87 patients.

Patients’ characteristics

Patients’ characteristics at the time of first exposure to CYC are detailed in Table 1. Mean age was 55.7 years, and 54.5% were women. In comparison with systemic vasculitis patients, SLE patients were younger, were more frequently female, had less frequent baseline kidney failure, had more frequent lymphopenia, and had been more frequently exposed to corticosteroids and immunosuppressive drugs before the exposure to CYC.

View this table:
  • View inline
  • View popup
Table 1.

Patients’ characteristics at CYC initiation. Values are n (%) unless otherwise specified.

Among the 12 patients who had a history of zoster, 8 were women and 4 had SLE. No patient had been vaccinated against VZV in the cohort at the time of exposure, nor thereafter during the followup.

The mean number of CYC pulses was 5.5 (range 1–9). The mean cumulative dose of CYC was 5605 ± 3214 mg (range 780–27,320; 8 missing values) and was comparable between SLE and vasculitis patients (5227 and 5748 mg, respectively). All patients were exposed to corticosteroids concomitantly to CYC. The mean exposure to corticosteroids was 2.6 years, and was higher in patients with SLE (4.1 vs 2.0 yrs in patients with vasculitis). Because of the retrospective design, we could not calculate the cumulative dose exposure to corticosteroids. During the year after the first exposure to CYC, 87.3% of the patients were exposed to another immunosuppressive drug (10.9% to ≥ 2 immunosuppressive drugs). Patients with SLE were more frequently exposed to mycophenolate mofetil (MMF) and less frequently exposed to rituximab (RTX) than the vasculitis patients (Table 1).

The mean followup from the first CYC pulse was 3.4 years (SD 1.7), corresponding to 355.9 PY. The mean followups were similar between SLE and vasculitis patients (3.3 ± 1.6 and 3.5 ± 1.7 yrs, respectively). Twelve patients (including 11 patients with systemic vasculitis) died during the followup: 4 sepsis (including 1 associated with alveolar hemorrhage and 1 associated with digestive ischemia complicating vasculitis), 2 intracranial bleeds, 1 B cell lymphoma, 1 prostate cancer, 1 respiratory distress due to vasculitis lung involvement, 1 refractory epilepsy complicating a cerebral vasculitis, and 2 unknown causes.

Exposure to VCV

Nineteen (17.2%) patients were exposed to VCV during the followup, given orally 500 mg once or twice a day. Two patients had a history of zoster, 5 had SLE and 16 started VCV concomitantly to CYC treatment. The mean duration of exposure to corticosteroids in these 19 patients was 3.6 years, and the mean cumulative dose of CYC was 5914 mg. Of note, 20.5% of the patients exposed to a high cumulative dose of CYC (> 3000 mg, which was the median cumulative dose of CYC in the cohort) were exposed to a prophylaxis with VCV, in contrast with 10.3% of the patients exposed to a lower cumulative dose of CYC. During the year after CYC, 15 of these patients were exposed to azathioprine, 3 to RTX, and 1 to MMF. Because of the retrospective design of the study, we could date precisely VCV withdrawal in 7 patients only; the mean duration of exposure was 396 days. No adverse drug reaction related to VCV was observed.

Incidence and description of zoster cases

Ten patients (9.1%) developed a zoster during the followup. The characteristics of these 10 cases of zoster are described in Table 2. Seven were treated for systemic vasculitis. Nine occurred in women and the mean age was 63 years. Only 1 patient had a previous history of zoster. Six cases occurred during the year after the first exposure to CYC (Table 2 and Figure 1). Seven patients were exposed to a prednisone-equivalent daily dose ≤ 15 mg at the time of zoster occurrence. Three patients were hospitalized for zoster management (Patients 3, 5, and 8 in Table 2). One patient (Patient 3 in Table 2) had a lumbar zoster extensive to the thigh, with favorable outcome after antiviral treatment. No bacterial infection complicating cutaneous lesions and no visceral dissemination was observed. One patient had a recurrence with herpes zoster ophthalmicus developing 15 months after the first episode, and 4 patients had postherpetic neuralgia.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Cumulative probability of zoster after cyclophosphamide initiation.

View this table:
  • View inline
  • View popup
Table 2.

Characteristics of the 10 zoster cases that occurred during the followup.

The overall incidence of zoster after exposure to CYC was 27.9/1000 PY (95% CI 15.2–50.6); it peaked during the year after CYC initiation with an incidence of 59.4/1000 patients (95% CI 27.5–123.6).

The incidence of zoster in patients with SLE was 34.5/1000 PY (95% CI 11.8–96.6); it peaked with 111/1000 PY (95% CI 38.5–280.6) during the year after CYC initiation. The incidence in patients treated for systemic vasculitis was 26.0/1000 PY (95% CI 12.6–52.7); it was 40.5/1000 PY (95% CI 13.9–112.5) during the year after CYC initiation.

Factors associated with zoster

The results of univariate analyses are shown in Table 3. There was an increased risk of zoster in case of lymphopenia < 500/µl at CYC initiation (HR 5.11, 95% CI 0.94–27.93) and in women (HR 4.36, 95% CI 0.51–37.31). The incidence was 2.7-fold higher in patients with SLE compared with systemic vasculitis patients (HR 2.68, 95% CI 0.54–13.26).

View this table:
  • View inline
  • View popup
Table 3.

Univariate analysis of factors associated with occurrence of zoster in the year after exposure to pulse intravenous CYC for systemic vasculitis or SLE (n = 110). Values are n (%) unless otherwise specified.

None of the 19 patients exposed to VCV during the followup developed zoster.

DISCUSSION

The incidence of zoster in this cohort was 6-fold higher (14-fold higher when considering the year after CYC initiation) than in the French general population in 2015 (estimated to be 4.19/1000 inhabitants)30,31.

This cohort study demonstrated the high incidence of zoster after intravenous CYC for systemic vasculitis or SLE, particularly during the year after CYC initiation and for patients with SLE. The cases of zoster were not extensive, but 30% of the patients were hospitalized and 40% had postherpetic neuralgia. Comparative analysis strongly suggested that female sex and lymphocyte count < 500/µl at CYC initiation were risk factors, and that prophylaxis by VCV was protective.

The incidence of zoster in patients with SLE in our cohort (34.5/1000 PY) was close to the incidence observed in the previously quoted nationwide Taiwanese SLE cohort (37.7/1000 PY), in which 22% of patients were treated with CYC12. Other retrospective studies found a lower incidence of zoster in SLE, ranging from 6.4 to 22.0/1000 PY. However, only 1–15% of the included patients had been exposed to CYC in these cohorts9,10,11.

Very few data exist regarding the incidence of zoster in systemic vasculitis. It was 26/1000 PY in our study, which is lower than the results from the WGET trial (45/1000 PY)17. Of note, 73% of the 180 patients with GPA included in the WGET trial had been exposed to CYC before the trial and 70% during the trial; 49% were also treated with etanercept, which may increase the risk of VZV reactivation32. The trend of an increased incidence of zoster in patients with SLE as compared with systemic vasculitis patients in our study could be partly explained by a higher frequency of lymphopenia in SLE and/or by a higher rate of exposure to immunosuppressive drugs prior to CYC initiation.

Six of the 10 cases of zoster occurred during the year after the first exposure to CYC, and 2 occurred more than 5 years after. Cohort studies led to contradictory results regarding the time of zoster occurrence in patients with SLE: some suggested that the risk of developing VZV reactivation is higher during the first year after SLE diagnosis33,34, while others suggested a higher incidence after years of inactive disease8,9,10,35,36. Similarly, studies in patients with systemic vasculitis suggested a higher risk of zoster when the disease is in complete remission16,17,37. However, CYC seems a strong risk factor for short-term severe infection and of zoster in these patients, as demonstrated in our study22,38,39,40,41. Of note, the short mean followup in our study (3.4 yrs) prevented us from estimating the longterm risk of zoster.

The rarity of disseminated zoster is in accordance with the literature, with a frequency of 10.9% of the cases of zoster observed in the SLE series by Kahl8. No local complication was observed in our cohort, in contrast with the study of Borba, et al, in which 11.7% of SLE patients with zoster had bacterial complications independent of disease activity, lymphopenia, and exposure to immunosuppressive drugs10. There were 30% of our patients who were hospitalized for zoster management. This is higher than the rate estimated for all immunocompromised patients in France (11.0%)28. However, the rate of hospitalization for zoster in patients with SLE is increasing, probably because of the complexity of SLE treatments and better access to specialist physicians42. Interestingly, the rate of postherpetic neuralgia was higher in our study (40%) than in previous SLE and GPA cohorts (ranging from 14% to 28%)9,10,16,17. Consequently, this finding suggests that exposure to CYC could be a risk factor for postherpetic neuralgia.

Our study suggests that female sex and lymphopenia < 500/µl at CYC initiation are risk factors for zoster. The incidence of zoster is higher among women in the general population43,44,45. However, data are conflicting in patients with SLE11,12,36 and GPA16,17,41. The finding that lymphopenia would be a strong risk factor for zoster development in patients with SLE and vasculitis is in accordance with previous literature36,40,46. Our study suggests that strong attention should be paid to lymphocyte count < 500/µl at CYC initiation. Because of the retrospective design, we could not measure lymphocyte subtypes and therefore their effect on zoster occurrence. A study in patients with AAV has demonstrated that a low CD4+ lymphocyte count is more predictive of infection occurrence than the total lymphocyte count41.

Older age is a risk factor for zoster in the general population45, but was not a risk factor for zoster in previous SLE and AAV cohorts5,13,38,39,41. This result is confirmed by our study. Nearly half of our population had a baseline renal failure. This was not a risk factor for zoster in our cohort. Literature shows discrepant results in SLE8,9,12,36, while renal involvement was associated to zoster occurrence in the WGET trial17.

Similarly, a higher cumulative dose of CYC was not associated with a higher risk of zoster in our study. Findings are conflicting in previous SLE cohorts13,22. In a prospective trial in patients with GPA comparing pulse intravenous and oral CYC (leading to higher cumulative doses), there was a 3-fold higher occurrence of zoster in patients exposed to oral CYC47. Of note, in our study, 20.5% of patients exposed to a cumulative dose of CYC > 3000 mg had prophylaxis with VCV, as compared with 10.3% of the patients exposed to a lower cumulative dose. This may have contributed to the finding of no influence of the cumulative dose of CYC on zoster occurrence.

Most importantly, no patient with prophylaxis developed zoster (including 2 with a previous history of zoster). Even if time-varying exposure could not be performed, this finding strongly suggests the efficacy of such prophylaxis in preventing zoster in systemic vasculitis and SLE patients treated with pulse intravenous CYC.

Our study has limitations, mainly due to the retrospective design. First, an underrecording of zoster cannot be ruled out but seems unlikely. Indeed, we used several sources to identify the outcome, and recall bias is unlikely for zoster. Second, some covariable values were missing, and we could not calculate the cumulative dose of corticosteroids. Similarly, we could not record the exact dates of withdrawal for all patients exposed to VCV, preventing time-varying analyses. Third, some variables that may have influenced the outcome occurrence, such as CD4+ lymphocyte count or serum γ-globulin level, were not available (both at baseline and at the time of zoster occurrence). Fourth, because two-thirds of the zoster cases occurred early after CYC initiation, we could not assess the effect of the exposure to other immunosuppressive drugs after CYC in this cohort (immortal time bias). Fifth, because of lack of statistical power, we could not conduct multivariate analyses. Similarly, because of the absence of zoster occurrence in patients exposed to prophylaxis with VCV, we could not compute any HR for this association, but this finding strongly suggests that such prophylaxis has a strong protective effect in this setting. Lastly, none of our patients had been vaccinated against VZV. Some studies showed that inactivated vaccine may be an efficient alternative prophylaxis strategy in patients having autoimmune diseases48,49. However, patients with SLE and systemic vasculitis are generally exposed to intravenous CYC urgently owing to severe flare, often at the disease onset in case of renal involvement. In the cases in which vaccination cannot be done before immunosuppressive drug exposure, prophylaxis by VCV is an effective option.

The incidence of zoster is high in patients with systemic vasculitis and SLE exposed to pulse intravenous CYC. Exposure to CYC may favor postherpetic neuralgia. In patients not vaccinated against VZV, prophylaxis with VCV should be considered, particularly in women, in case of lymphopenia < 500/µl at CYC initiation and during the year after.

  • Accepted for publication May 23, 2018.

REFERENCES

  1. 1.↵
    1. Werner RN,
    2. Nikkels AF,
    3. Marinović B,
    4. Schäfer M,
    5. Czarnecka-Operacz M,
    6. Agius AM,
    7. et al.
    European consensus-based (S2k) Guideline on the Management of Herpes Zoster - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), part 1: diagnosis. J Eur Acad Dermatol Venereol 2017;31:9–19.
    OpenUrl
  2. 2.↵
    1. Chen SY,
    2. Suaya JA,
    3. Li Q,
    4. Galindo CM,
    5. Misurski D,
    6. Burstin S,
    7. et al.
    Incidence of herpes zoster in patients with altered immune function. Infection 2014;42:325–34.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Chakravarty EF
    . Viral infection and reactivation in autoimmune disease. Arthritis Rheum 2008;58:2949–57.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Chakravarty EF
    . Incidence and prevention of herpes zoster reactivation in patients with autoimmune diseases. Rheum Dis Clin North Am 2017;43:111–21.
    OpenUrl
  5. 5.↵
    1. Yun H,
    2. Yang S,
    3. Chen L,
    4. Xie F,
    5. Winthrop K,
    6. Baddley JW,
    7. et al.
    Risk of herpes zoster in autoimmune and inflammatory diseases: implications for vaccination. Arthritis Rheumatol 2016;68:2328–37.
    OpenUrl
  6. 6.↵
    1. Tran CT,
    2. Ducancelle A,
    3. Masson C,
    4. Lunel-Fabiani F
    . Herpes zoster: risk and prevention during immunomodulating therapy. Joint Bone Spine 2017;84:21–7.
    OpenUrl
  7. 7.↵
    1. Marra F,
    2. Lo E,
    3. Kalashnikov V,
    4. Richardson K
    . Risk of Herpes zoster in individuals on biologics, disease-modifying antirheumatic drugs, and/or corticosteroids for autoimmune diseases: a systematic review and meta-analysis. Open Forum Infect Dis 2016;3:ofw205.
    OpenUrlCrossRef
  8. 8.↵
    1. Kahl LE
    . Herpes zoster infections in systemic lupus erythematosus: risk factors and outcome. J Rheumatol 1994;21:84–6.
    OpenUrlPubMed
  9. 9.↵
    1. Manzi S,
    2. Kuller LH,
    3. Kutzer J,
    4. Pazin GJ,
    5. Sinacore J,
    6. Medsger TA,
    7. et al.
    Herpes zoster in systemic lupus erythematosus. J Rheumatol 1995;22:1254–8.
    OpenUrlPubMed
  10. 10.↵
    1. Borba EF,
    2. Ribeiro AC,
    3. Martin P,
    4. Costa LP,
    5. Guedes LK,
    6. Bonfá E
    . Incidence, risk factors, and outcome of Herpes zoster in systemic lupus erythematosus. J Clin Rheumatol 2010;16:119–22.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Chakravarty EF,
    2. Michaud K,
    3. Katz R,
    4. Wolfe F
    . Increased incidence of herpes zoster among patients with systemic lupus erythematosus. Lupus 2013;22:238–44.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Chen HH,
    2. Chen YM,
    3. Chen TJ,
    4. Lan JL,
    5. Lin CH,
    6. Chen DY
    . Risk of herpes zoster in patients with systemic lupus erythematosus: a three-year follow-up study using a nationwide population-based cohort. Clinics 2011;66:1177–82.
    OpenUrl
  13. 13.↵
    1. Hu SC,
    2. Yen FL,
    3. Wang TN,
    4. Lin YC,
    5. Lin CL,
    6. Chen GS
    . Immunosuppressive medication use and risk of herpes zoster (HZ) in patients with systemic lupus erythematosus (SLE): A nationwide case-control study. J Am Acad Dermatol 2016;75:49–58.
    OpenUrl
  14. 14.↵
    1. Singh JA,
    2. Hossain A,
    3. Kotb A,
    4. Oliveira A,
    5. Mudano AS,
    6. Grossman J,
    7. et al.
    Treatments for lupus nephritis: a systematic review and network metaanalysis. J Rheumatol 2016;43:1801–15.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Hoffman GS,
    2. Kerr GS,
    3. Leavitt RY,
    4. Hallahan CW,
    5. Lebovics RS,
    6. Travis WD,
    7. et al.
    Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488–98.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Charlier C,
    2. Henegar C,
    3. Launay O,
    4. Pagnoux C,
    5. Berezné A,
    6. Bienvenu B,
    7. et al.
    Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients. Ann Rheum Dis 2009;68:658–63.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Wung PK,
    2. Holbrook JT,
    3. Hoffman GS,
    4. Tibbs AK,
    5. Specks U,
    6. Min YI,
    7. et al;
    8. WGET Research Group
    . Herpes zoster in immunocompromised patients: incidence, timing, and risk factors. Am J Med 2005;118:1416.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Bertsias G,
    2. Ioannidis JP,
    3. Boletis J,
    4. Bombardieri S,
    5. Cervera R,
    6. Dostal C,
    7. et al.
    EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008;67:195–205.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Gordon C,
    2. Amissah-Arthur MB,
    3. Gayed M,
    4. Brown S,
    5. Bruce IN,
    6. D’Cruz D,
    7. et al.
    The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology 2018;57:e1–45.
    OpenUrl
  20. 20.↵
    1. Yates M,
    2. Watts RA,
    3. Bajema IM,
    4. Cid MC,
    5. Crestani B,
    6. Hauser T,
    7. et al.
    EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 2016;75:1583–94.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Hoffman GS,
    2. Leavitt RY,
    3. Fauci AS
    . Infectious complications of cyclophosphamide treatment for vasculitis. Arthritis Rheum 1989;32:1626–7.
    OpenUrlPubMed
  22. 22.↵
    1. Houssiau FA,
    2. Vasconcelos C,
    3. D’Cruz D,
    4. Sebastiani GD,
    5. Garrido Ed Ede R,
    6. Danieli MG,
    7. et al.
    Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002;46:2121–31.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Baden LR,
    2. Swaminathan S,
    3. Angarone M,
    4. Blouin G,
    5. Camins BC,
    6. Casper C,
    7. et al.
    Prevention and treatment of cancer-related infections, version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw 2016;14:882–913.
    OpenUrl
  24. 24.↵
    1. Seo HM,
    2. Kim YS,
    3. Bang CH,
    4. Lee JH,
    5. Lee JY,
    6. Lee DG,
    7. et al.
    Antiviral prophylaxis for preventing herpes zoster in hematopoietic stem cell transplant recipients: a systematic review and meta-analysis. Antiviral Res 2017;140:106–15.
    OpenUrl
  25. 25.↵
    1. Hochberg MC
    . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Jennette JC,
    2. Falk RJ,
    3. Bacon PA,
    4. Basu N,
    5. Cid MC,
    6. Ferrario F,
    7. et al.
    2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013;65:1–11.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Johnson RW,
    2. Rice AS
    . Clinical practice. Postherpetic neuralgia. N Engl J Med 2014;371:1526–33.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Gonzalez Chiappe S,
    2. Sarazin M,
    3. Turbelin C,
    4. Lasserre A,
    5. Pelat C,
    6. Bonmarin I,
    7. et al.
    Herpes zoster: Burden of disease in France. Vaccine 2010;28:7933–8.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Levey AS,
    2. Stevens LA,
    3. Schmid CH,
    4. Zhang YL,
    5. Castro AF,
    6. Feldman HI,
    7. et al;
    8. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
    . A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604–12.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Flahault A,
    2. Blanchon T,
    3. Dorléans Y,
    4. Toubiana L,
    5. Vibert JF,
    6. Valleron AJ
    . Virtual surveillance of communicable diseases: a 20-year experience in France. Stat Methods Med Res 2006;15:413–21.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Sentinelles network
    . Herpes zoster in France. 2015. [Internet. Web page in French. Accessed June 22, 2018]. Available from: websenti.u707.jussieu.fr/sentiweb/?page=maladies&mal=14
  32. 32.↵
    1. Che H,
    2. Lukas C,
    3. Morel J,
    4. Combe B
    . Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis. Joint Bone Spine 2014;81:215–21.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Nagasawa K,
    2. Yamauchi Y,
    3. Tada Y,
    4. Kusaba T,
    5. Niho Y,
    6. Yoshikawa H
    . High incidence of herpes zoster in patients with systemic lupus erythematosus: an immunological analysis. Ann Rheum Dis 1990;49:630–3.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Pope JE,
    2. Krizova A,
    3. Ouimet JM,
    4. Goodwin JL,
    5. Lankin M
    . Close association of herpes zoster reactivation and systemic lupus erythematosus (SLE) diagnosis: case-control study of patients with SLE or noninflammatory nusculoskeletal disorders. J Rheumatol 2004;31:274–9.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    1. Sayeeda A,
    2. Al Arfaj H,
    3. Khalil N,
    4. Al Arfaj AS
    . Herpes zoster infections in SLE in a university hospital in Saudi Arabia: risk factors and outcomes. Autoimmune Dis 2010;2011:174891.
    OpenUrl
  36. 36.↵
    1. Hu SC,
    2. Lin CL,
    3. Lu YW,
    4. Chen GS,
    5. Yu HS,
    6. Wu CS,
    7. et al.
    Lymphopaenia, anti-Ro/anti-RNP autoantibodies, renal involvement and cyclophosphamide use correlate with increased risk of herpes zoster in patients with systemic lupus erythematosus. Acta Derm Venereol 2013;93:314–8.
    OpenUrl
  37. 37.↵
    1. Cupps TR,
    2. Silverman GJ,
    3. Fauci AS
    . Herpes zoster in patients with treated Wegener’s granulomatosis. A possible role for cyclophosphamide. Am J Med 1980;69:881–5.
    OpenUrlPubMed
  38. 38.↵
    1. Pryor BD,
    2. Bologna SG,
    3. Kahl LE
    . Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Arthritis Rheum 1996;39:1475–82.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Cavallasca JA,
    2. Costa CA,
    3. Maliandi Mdel R,
    4. Contini LE,
    5. Fernandez de Carrera E,
    6. Musuruana JL
    . Severe infections in patients with autoimmune diseases treated with cyclophosphamide. Reumatol Clin 2015;11:221–3.
    OpenUrl
  40. 40.↵
    1. Morton M,
    2. Edmonds S,
    3. Doherty AM,
    4. Dhaygude A,
    5. Helbert M,
    6. Venning M
    . Factors associated with major infections in patients with granulomatosis with polyangiitis and systemic lupus erythematosus treated for deep organ involvement. Rheumatol Int 2012;32:3373–82.
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Shi YY,
    2. Li ZY,
    3. Zhao MH,
    4. Chen M
    . The CD4 lymphocyte count is a better predictor of overall infection than the total lymphocyte count in ANCA-associated vasculitis under a corticosteroid and cyclophosphamide regimen: a retrospective cohort. Medicine 2015;94:e843.
    OpenUrl
  42. 42.↵
    1. Murray SG,
    2. Schmajuk G,
    3. Trupin L,
    4. Gensler L,
    5. Katz PP,
    6. Yelin EH,
    7. et al.
    National lupus hospitalization trends reveal rising rates of herpes zoster and declines in pneumocystis pneumonia. PLoS One 2016;11:e0144918.
    OpenUrl
  43. 43.↵
    1. Pinchinat S,
    2. Cebrián-Cuenca AM,
    3. Bricout H,
    4. Johnson RW
    . Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis 2013;13:170.
    OpenUrlCrossRefPubMed
  44. 44.↵
    1. Thomas SL,
    2. Hall AJ
    . What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis 2004;4:26–33.
    OpenUrlCrossRefPubMed
  45. 45.↵
    1. Johnson BH,
    2. Palmer L,
    3. Gatwood J,
    4. Lenhart G,
    5. Kawai K,
    6. Acosta CJ
    . Annual incidence rates of herpes zoster among an immunocompetent population in the United States. BMC Infect Dis 2015;15:502.
    OpenUrlCrossRefPubMed
  46. 46.↵
    1. Goupil R,
    2. Brachemi S,
    3. Nadeau-Fredette AC,
    4. Déziel C,
    5. Troyanov Y,
    6. Lavergne V,
    7. et al.
    Lymphopenia and treatment-related infectious complications in ANCA-associated vasculitis. Clin J Am Soc Nephrol 2013;8:416–23.
    OpenUrlAbstract/FREE Full Text
  47. 47.↵
    1. Guillevin L,
    2. Cordier JF,
    3. Lhote F,
    4. Cohen P,
    5. Jarrousse B,
    6. Royer I,
    7. et al.
    A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener’s granulomatosis. Arthritis Rheum 1997;40:2187–98.
    OpenUrlCrossRefPubMed
  48. 48.↵
    1. Zhang J,
    2. Xie F,
    3. Delzell E,
    4. Chen L,
    5. Winthrop KL,
    6. Lewis JD,
    7. et al.
    Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 2012;308:43–9.
    OpenUrlCrossRefPubMed
  49. 49.↵
    1. Eberhardson M,
    2. Hall S,
    3. Papp KA,
    4. Sterling TM,
    5. Stek JE,
    6. Pang L,
    7. et al.
    Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with autoimmune disease: a phase 2, randomized, double-blind, placebo-controlled clinical trial. Clin Infect Dis 2017;65:1174–82.
    OpenUrl
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 45, Issue 11
1 Nov 2018
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Zoster after Cyclophosphamide for Systemic Lupus Erythematosus or Vasculitis: Incidence, Risk Factors, and Effect of Antiviral Prophylaxis
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Zoster after Cyclophosphamide for Systemic Lupus Erythematosus or Vasculitis: Incidence, Risk Factors, and Effect of Antiviral Prophylaxis
Camille Garnier, David Ribes, Dominique Chauveau, Antoine Huart, Grégory Pugnet, Daniel Adoue, Grégoire Prevot, Laurent Alric, Pierre Delobel, Hélène Derumeaux, Catherine Mengelle, Laurent Sailler, Guillaume Moulis
The Journal of Rheumatology Nov 2018, 45 (11) 1541-1548; DOI: 10.3899/jrheum.180310

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Zoster after Cyclophosphamide for Systemic Lupus Erythematosus or Vasculitis: Incidence, Risk Factors, and Effect of Antiviral Prophylaxis
Camille Garnier, David Ribes, Dominique Chauveau, Antoine Huart, Grégory Pugnet, Daniel Adoue, Grégoire Prevot, Laurent Alric, Pierre Delobel, Hélène Derumeaux, Catherine Mengelle, Laurent Sailler, Guillaume Moulis
The Journal of Rheumatology Nov 2018, 45 (11) 1541-1548; DOI: 10.3899/jrheum.180310
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • REFERENCES
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters

Keywords

HERPES ZOSTER
SYSTEMIC LUPUS ERYTHEMATOSUS
SYSTEMIC VASCULITIS
ANCA-ASSOCIATED VASCULITIS
VALACYCLOVIR
EPIDEMIOLOGY

Related Articles

Cited By...

More in this TOC Section

  • Association of Health Literacy and Numeracy With Lupus Knowledge and the Creation of the Lupus Knowledge Assessment Test
  • A Distinct Plasma Microbiome But Not Gut Microbiome in Patients With Systemic Lupus Erythematosus Compared to Healthy Individuals
  • Gestational Diabetes Mellitus Risk in Pregnant Women With Systemic Lupus Erythematosus
Show more Systemic Lupus Erythematosus

Similar Articles

Keywords

  • HERPES ZOSTER
  • systemic lupus erythematosus
  • SYSTEMIC VASCULITIS
  • ANCA-associated vasculitis
  • VALACYCLOVIR
  • epidemiology

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire